Overview

The reauthorization of the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs is a signal to researchers and entrepreneurs on the renewed federal commitment to the early-stage, high-risk scientific innovation that defines the biosciences.
For New York’s health and life sciences community, the reauthorization preserves and expands the mechanisms that make SBIR and STTR uniquely valuable: non-dilutive capital that lets innovators de-risk their science without surrendering equity, intellectual property, or strategic direction. Layered on top of the federal programs, New York State has assembled a complementary suite of matching funds, tax incentives, and access to private capital that makes the overall funding environment exceptionally well-suited for companies and research teams at nearly every stage.

UNDERSTANDING NON-DILUTIVE FUNDING
SBIR and STTR grants are non-dilutive, making them a powerful funding instruments available to early-stage life sciences companies. These federal awards require no equity exchange and no compromise of your IP position. The federal government, in effect, becomes a strategic partner in de-risking your technology before engaging the private markets engage.
The STTR variant has one key distinction from SBIR: it requires a formal collaboration agreement with a research institution, a university, nonprofit, or federal lab. For New York innovators, STTR is a natural fit and an opportunity to leverage New York’s exceptional institutions for funded partnerships.
The funding operates through a three-phase structure designed to take innovations from concept to the commercialization phase:
Phase I: Proof of Concept (up to ~$275,000 | 6–12 months): Entry point that supports feasibility studies and proof-of-concept research.
Phase II: Technology Development (up to ~$1.8 million | 24 months): Full-scale R&D, prototype development, and validation.
Phase III: Commercialization: The commercialization phase is supported through private capital, federal procurement contracts, or partnerships. SBIR/STTR funding does not apply here, but your track record through Phases I and II is a powerful signal to investors and future partners.

FEDERAL FUNDING: MULTIPLE AGENCIES, MULTIPLE ENTRY POINTS
The SBIR/STTR funding is granted through eleven federal agencies. As life sciences, health, and biosciences are increasingly intertwined with national priorities across multiple departments, the relevant doors extend well beyond Health. The following agencies present their own funding focus, application timelines, and strategic priorities.

Health and Human Services (HHS):The primary home for most life sciences SBIR/STTR awards spanning disease research, diagnostics, therapeutics, health technology.
Department of War (DoW): National defense is a high-priority investment area for the current administration, and health-bioscience applications are actively sought. These can include biodefense, medical countermeasures, field diagnostics, warfighter health.
Department of Energy (DoE):Strong fit for industrial biotech and sustainability-focused innovations including bioenergy, synthetic biology, bioprocessing, and environmental applications.
Department of Agriculture (USDA): Agricultural biotech, food safety, plant genomics, and rural health. Relevant for companies operating at the ag-bio interface.
National Science Foundation (NSF):Foundational science, data-driven biology, and cross-disciplinary bioscience research with commercial potential.

Key Considerations When Pursuing Federal SBIR/STTR Funding
Assess the funding category carefully. The number of topic areas an agency solicitation spans signals how defined or open the research agenda is. Broader solicitations give you more positioning latitude; narrower ones require a tighter fit. Either way, understand what the agency is seeking before you apply.
Consider multi-application positioning. Does your innovation have applications in more than one sector? Health and biosciences are explicitly relevant to national defense, energy security, and agricultural resilience. When applying for multidisciplinary federal funding, identify and articulate those adjacent implications clearly to strengthen your case.
Build your timeline early. Award cycles vary by agency. From solicitation review to award, federal funding takes time with cycles often running 6 to 12 months. Planning your submission calendar and maintaining eligibility (small business status, U.S. headquarters, key personnel requirements) should be part of your ongoing operational rhythm.
New York Bio Connect aggregates open and upcoming federal funding opportunities relevant to health and life sciences.

NEW YORK STATE: THE MULTIPLIER EFFECT
Federal SBIR/STTR awards compound their powerful when combined with New York State’s complementary programs. The state has deliberately built infrastructure to amplify federal investment in innovation with matching grants, sector-specific funds, and incentive structures that reward exactly the kind of science-to-market work that defines successful bioscience commercialization.
NYSTAR Innovation Matching Grant (SBIR/STTR)
Administered by the New York State Foundation for Science, Technology and Innovation (NYSTAR), this program provides matching funds to New York–based companies or those willing to relocate to New York, that have received a Phase I or Phase II SBIR/STTR award. It is one of the most direct and actionable programs with about $70 million in annual funding distributed through a vital cross-state network. NYSTAR Executive Director Ben Verschueren said, “The Innovation Matching Grants program bridges the gap between R&D and commercialization — the hardest step for many early-stage technology companies. This state investment gives entrepreneurs the resources to protect and market their intellectual property, attract investors and move their promising projects into everyday use.”
New York State Biodefense Commercialization Fund
Targeting companies developing technologies with biodefense and biosecurity applications — an area of increasing federal and state priority — this fund provides capital to support the commercialization of innovations that protect public health and national security. Companies with dual-use technologies (civilian health and biodefense applications) are particularly well-positioned. Since the program’s inception in 2021, $40 million has been awarded 27 grantees.
New York State Innovation Venture Capital Fund
For companies ready to engage private capital markets, the NYS Innovation Venture Capital Fund provides bridge funding and co-investment support, connecting state resources to private capital activity. 33% of the portfolio represent health care/ life sciences that have benefited from the state’s $100 million VC fund.

PRIVATE INVESTMENT: THE CAPITAL STACK COMPLETION
Non-dilutive federal and state funding de-risks your technology. Private investment scales it. These capital sources should be treated as deliberate components of a funding strategy, using grants and matching funds to reach inflection points that make them attractive to investors, then engaging private capital to accelerate.
New York Bio Connect features three private investment opportunities with specific bioscience expertise:
Mid-Atlantic Bio Angels — An angel investor network with deep life sciences expertise and a focus on early-stage bioscience companies. Their members bring both capital and domain knowledge, making them strategic partners as well as investors.
Upstate Biotech Ventures — A regionally focused venture vehicle with a mandate to invest in Upstate New York’s growing bioscience ecosystem.
2048 Ventures — An early-stage NYC-based venture fund with an active portfolio in technology-enabled life sciences. They invest across sectors but have demonstrated consistent interest in companies at the science-to-product transition.